Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment.
Journal of Rheumatology 2023 April 2
Arthritis induced by immune checkpoint inhibitors (ICPi) has been reported to occur in 1% to 7% of ICPi-treated patients with cancer.1-4 Treatment generally starts with glucocorticoids (GCs) before disease-modifying antirheumatic drugs (DMARDs) are considered.5 .
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app